The specialist for diabetic products, Novo Nordisk presented the data of oral semaglutide. Oral semaglutide showed superiority over Jardiance, non-inferiority versus Victoza in adult patients suffering from type-2 diabetes at week 26 and week 52.
About PIONEER-2 AND PIONEER-4 STUDIES:
Endpoint: Reduction in HbA1c
Results: At week 26: 1.4% in patients on oral semaglutide vs. 0.9% in patients on empagliflozin
At week 52: 1.3% in patients on oral semaglutide vs. 0.8% in patients on empagliflozin
Endpoint: Reduction in HbA1c
Results: At week 26: 1.3% in patients on oral semaglutide vs. 1.1% in patients on Victoza
At week 52: 1.2% in patients on oral semaglutide vs. 0.9% in patients on Victoza
Eli Lilly presented the data of tirzepatide demonstrating its potential to reduce the A1C and body weight in patients suffering from type 2 diabetes mellitus. Tirzepatide is a dual G1P and GLP-1 receptor agonist.
The poster highlighted:
Improvement in insulin sensitivity and beta cell function
A1C reduction and weight loss
Non-alcoholic steatohepatitis markers improved in patients suffering from type 2 diabetes mellitus
Tirzepatide showed a significant reduction in A1C (up to 2.0%) and weight loss (up to 5.7 kg)
Mild gastrointestinal adverse events were reported
Eli Lilly presented the data of Trulicity demonstrating the significant reduction of cardiovascular events in patients suffering from type 2 diabetes. Trulicity (dulaglutide) administered once weekly.
About REWIND data:
Endpoint: Reduction in major cardiovascular events
Results: Value of risk reduction are
CV death: 0.78 to 1.06
Non-fatal heart attack: 0.79 - 1.16
Non-fatal stroke : 0.61 - 0.95
Eli Lilly presented the data of ultra-rapid lispro demonstrating non-inferiority compared to Humalog (insulin lispro) after 26 weeks in patients suffering from type 1 and 2 diabetes mellitus.
About PRONTO-T1D and PRONTO-T2D (Phase 3):
The studies included 1,222 and 673 patients respectively.
Endpoint: Non-inferiority in A1C reduction
Results: Glucose monitoring was performed continuously. In the day time, ultra-rapid lispro showed better efficacy than insulin lispro. It showed similar efficacy as Humalog at night time.
Eli Lilly has presented efficacy of Tradjenta (linagliptin). In CAROLINA trial, it was demonstrated linagliptin did not increase cardiovascular risk. Glimepiride was used as a comparator in patients with type 2 diabetes mellitus.
About CAROLINA study:
Endpoint: 3P MACE
Results: 11.8% on Tradjenta arm vs. 12.0% on glimepride arm
Abbott’s presented the data of Freestyle Libre System showing the significant reduction in HbA1C levels. FreeStyle Libre System is a continuous glucose monitoring system. The research was conducted in 363 patients in France, Germany, and Austria. HbA1c levels were dropped by 1%. No major difference found in terms of age, sex and BMI.
The Freestyle Libre System is currently available in 46 countries, with more than 1.5 million patients using it.
Sanofi presented the data of Soliqua in adult patients suffering from type-2 diabetes mellitus. Soliqua/Suliqua (insulinglargine + lixisenatide) shown superiority in the reduction of HbA1c after 26 weeks.
About the Phase 3 study:
Soliqua was compared with GLP-1 RA therapy. The study included 514 adult patients with type-2 diabetes mellitus.
Endpoint: Reduction in blood sugar level (HbA1c) after 26 weeks.
Results: 0.6% greater reduction in HbA1c versus GLP-1 RA treatment.
Sanofi has presented a head-to-head study of Toujeo (insulin glargine injection) versus Tresiba (insulin degludec).
About the BRIGHT study:
Endpoint: Reduction in blood sugar level (HbA1C)
Results: -1.72% on Toujeo arm vs. -1.30% on Tresiba arm
Lower event rate in patients with the normal renal function was observed in Toujeo arm compared to Tresiba arm (6.5 vs. 10.4 events/patient/year)